Dr Reddy’s Laboratories (DRL) has launched Divalproex sodium extended – release tablets, USP (250 mg and 500 mg), a therapeutic equivalent generic version of Depakote ER (divalproex sodium) Tablet, extended release in the US market. DRL’s ANDA for Divalproex sodium extended- release tablets, USP was approved by the United States Food & Drug Administration (US FDA).
The Depakote ER brand and generic had combined US sales of approximately $194 million MAT for the most recent twelve months ending in June 2013 according to IMS Health. DRL’s Divalproex sodium extended – release tablets, USP 250 mg are available in bottle count sizes of 100 and 500 mg are available in bottle count sizes of 100 and 500.
EP News Bureau – Mumbai